Details of the Drug
General Information of Drug (ID: DMPKBVR)
| Drug Name |
2-acetamido-5-sulfonamidoindane
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
CHEMBL184674; N-(5-Sulfamoyl-indan-2-yl)-acetamide; 2-acetamido-5-sulfonamidoindane; Indanesulfonamide Derivative 6; SCHEMBL1971499; N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)acetamide; BDBM11029; CTK6A0685; RVPDXKXWYPPTAL-UHFFFAOYSA-N; N-acetyl-5-sulfamyl-2-indanamine; Acetamide, N-[5-(aminosulfonyl)-2,3-dihydro-1H-inden-2-yl]-; AKOS015966079; 74124-93-9
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 254.31 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 0.2 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||


